通过虚拟查,分子对接和分子动力学模拟来识别潜在的JNK3抑制剂,作为阿尔茨海默病治疗药物
Bharti Devi1, Kailash Jangid2, Naveen Kumar1
1Laboratory of Organic and Medicinal Chemistry, Department of Chemistry, School of Basic Sciences, Central University of Punjab, Bathinda, Ghudda, 151401, India.
Molecular diversity
|April 4, 2024
概括
研究人员通过向c-Jun N-终端激酶 (JNKs) 来确定阿尔茨海默病的新药候选者. 这项研究使用基于结构的虚拟查来发现AD治疗潜在的JNK抑制剂.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 计算化学的计算化学
背景情况:
- 阿尔茨海默病 (AD) 是一种复杂的神经系统疾病,没有有效的治疗方法.
- c-Jun N-终端激酶 (JNKs),特别是JNK3,与AD病理有关,包括神经炎症和神经元亡.
- 准JNK3为AD提供了潜在的治疗策略.
研究的目的:
- 开发新的JNK3抑制剂作为阿尔茨海默病的潜在治疗方法.
- 采用基于结构的虚拟选 (SBVS) 方法来识别化合物.
- 评估已识别的JNK3抑制剂的疗效和特性.
主要方法:
- 在ZINC数据库 (14,634,052个化合物) 上使用基于结构的虚拟选 (SBVS).
- 应用过器用于泛分析干扰 (PAINS),药物相似性和多样性挑选.
- 使用高通量虚拟选 (HTVS),标准精度 (SP),超精度 (XP) 和MMGBSA用于对接和绑定能量计算.
- 对化合物进行了100ns的分子动态模拟.
主要成果:
- 与参考化合物相比,确定了5个分子,具有较高的对接分数.
- 化合物表现出有利的药理动力学特性.
- 分子动力学模拟证实了整个轨迹的稳定相互作用和键.
- 计算的结合自由能量 (∆GMM/PBSA总) 分数在化合物中从-31.39到-42.8kcal/mol不等.
结论:
- 鉴定到的分子显示出作为强大的JNK3抑制剂的潜力.
- 这些化合物需要进一步研究作为阿尔茨海默病的治疗药物.
- 在发现新型JNK3抑制剂方面,SBVS方法被证明是有效的.
更多相关视频
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
832
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
563
相关概念视频
Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184
Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
